Skip to main content

Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC)


Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC)

Respiratory infections, frequently caused by drug-resistant bacteria, are the main cause of disease and death in people with cystic fibrosis (CF) and bronchiectasis (BE). Thanks to inhaled antibiotics, patients now live longer than ever before and enjoy a better quality of life. However, infections are increasingly becoming resistant to the few drugs available, putting patients’ lives at risk.

The iABC project is advancing the development of two inhaled antibiotics for patients with CF and BE. It is also working to identify ways of improving clinical trials of treatments for these serious diseases.

About Us
What is the iABC project?
About the Project
Clinical trials
What is the progress so far
Clinical Trials
View our dissemination activities
Video stories
Hear directly from those involved
Video Stories
What related events are coming up
EMBARC registry
Patients with non-CF bronchiectasis
EMBARC Registry